Question Bank › The product is disappearing into reorder rhythm

The product is disappearing into reorder rhythm

The product is disappearing into reorder rhythm: revenue is shifting from won-each-time to arriving-on-its-own, and the

Calls Tested
500
Answered YES
5
Hit Rate
1%
rare by design

Bristol-Myers Squibb Company (BMY) — this company's answers

NO on the Q4 2016 call 2017-01-26 F
The model's full reasoning — Q4 2016 call → NOWe need answer only YES or NO. Need analyze transcript. Question asks: Does management describe that a growing share of company's revenue now arrives without a new selling event — through reorders, refills, renewals, repeat purchases, usage-driven billing, aftermarket/consumable pull-through, or customers' own standing routines — AND that this self-arriving share has recently and visibly grown as proportion of business, with management grounding shift in observed current behavior and treating it as changing quality of revenue? We need use only transcript. Need determine if management describes such. The transcript is Bristol-Myers Squibb Q4 2016 earnings call. They discuss Opdivo, Eliquis, etc. Need see if any mention of recurring revenue, reorders, refills, renewals, repeat purchases? This is pharma, sales of drugs. Revenue from prescriptions, not necessarily "self-arriving" without selling event? They discuss demand growth, inventory, market share. But question specifically about "growing share of revenue now arrives without a new selling event" like reorders/refills/renewals. In pharma, prescriptions are repeat purchases? But management likely doesn't describe such. Need look for any language about "repeat" or "recurring" or "installed base" etc. The transcript includes commercial discussions about Opdivo, Eliquis, etc. No mention of recurring revenue model. They talk about "demand growth", "inventory work-down", "reimbursement", "uptake curves". Not about self-arriving revenue. There is mention of "non-promoted sales" in small-cell lung cancer and miscellaneous tumors. That could be off-label usage? But not self-arriving revenue from installed base? They mention "non-promoted sales" meaning sales without promotion? But not necessarily recurring. Also "customers' own standing routines" no. Question asks YES if management conveys one coherent recent shift with both halves. Likely NO. Need be careful: Could "Opdivo" has ongoing treatment cycles, patients continue therapy, so revenue from existing patients? But management doesn't discuss that as a shift. They discuss "demand growth" but not "self-arriving share". They discuss "international business" with reimbursement, "deferred revenues" recognized. Not about repeat mechanism. Thus answer NO.

← Back to the full BMY analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that a GROWING SHARE OF THE COMPANY'S REVENUE NOW ARRIVES WITHOUT A NEW SELLING EVENT — through reorders, refills, renewals, repeat purchases, usage-driven billing, aftermarket or consumable pull-through, or customers' own standing routines — AND that this self-arriving share has RECENTLY AND VISIBLY GROWN as a proportion of the business, with management grounding the shift in observed current behavior and treating it as changing the company's quality of revenue? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent recent shift with both halves present: (1) SELF-ARRIVING REVENUE, OBSERVED NOW: management points to real, current repeat-mechanism revenue — reorder rates, renewal behavior, consumable or aftermarket attach, usage growth from installed product, or customers reordering on their own schedule — described with concrete grounding in the recent period, not asserted through generic 'recurring revenue' or 'loyal customers' language; and (2) THE PROPORTION HAS RECENTLY MOVED: management conveys that this self-arriving component is a visibly LARGER share of the business than it recently was — through an installed base that has recently scaled, a consumable or service stream now compounding on top of equipment already placed, or repeat behavior recently strengthening — so the company's revenue is becoming progressively less dependent on winning each sale, with the mix still early in its shift. Answer NO if the business has always been overwhelmingly recurring or contractual with nothing recently shifted. NO if repeat language is boilerplate with no observed behavior or recent change. NO if the repeat revenue is forced by contract lock-in with no customer choice described. NO if the shift is only planned or hoped for. NO if the pattern rests on one anecdote, or appears only in an analyst's question management does not affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
DUOT Duos Technologies Group, Inc. Q4 2023 2024-04-01 F
QTRX Quanterix Corporation Q3 2023 2023-11-07 B
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
IRBT iRobot Corporation Q3 2021 2021-10-28 D
TOUR Tuniu Corporation Q4 2017 2018-03-14 D

How the model reasoned

DUOT · Q4 2023 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, through reorders, renewals, etc., and that this has recently and visibly grown as a ...
QTRX · Q3 2023 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, like through reorders, consumables, etc., and that this share has recently grown.
CYBR · Q3 2021 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, like through renewals, and that this has recently grown as a proportion.

More from the question bank

Named catch-up gapWorking for customers it could not have servPaid to expand: the company's growth spendinVolume records through a still-fixed gateRecently unlocked doorSelling something whose payoff to the buyer All questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.